2 research outputs found
ACPA-negative RA consists of subgroups: patients with high likelihood of achieving sustained DMARD-free remission can be identified by serological markers at disease presentation
Background: Disease-modifying antirheumatic drug (DMARD)-free remission, the sustained absence of synovitis
after DMARD cessation, is increasingly achievable, especially in autoantibody-negative rheumatoid arthritis (RA).
However, underlying mechanisms are unknown and patient subgroups that achieve this outcome are insufficiently
characterized. We evaluated whether serological biomarkers at disease onset, as measured within the multibiomarker disease activity (MBDA) score, are differently expressed in RA patients who achieve sustained DMARDfree remission.
Methods: Two hundred ninety-nine RA patients were evaluated for achievement of sustained DMARD-free remission
during a median follow-up of 4.3 years. Twelve biomarkers, as included in the MBDA score, were determined from the
serum obtained at disease onset. Patients were categorized as having a low ( 44)
score. Analyses were stratified for anti-citrullinated protein antibodies (ACPA) based under the assumption that ACPApositive and ACPA-negative RA are different disease entities.
Results: Twenty percent achieved sustai
Does treatment strategy influence the ability to achieve and sustain DMARD-free remission in patients with RA? Results of an observational study comparing an intensified DAS-steered treatment strategy with treat to target in routine care
Objectives: To study the impact of treatment strategy on achieving and sustaining disease-modifying antirheumatic
drug (DMARD)-free remission in patients with rheumatoid arthritis (RA).
Methods: Two hundred seventy-nine RA patients (median follow-up 7.8 years) were studied. Of these, 155 patients
participated in a disease activity score (DAS) < 1.6 steered trial aimed at DMARD-free remission. Initial treatment
comprised methotrexate with high-dose prednisone (60 mg/day) and a possibility to start biologicals after 4 months. In
the same period and hospital, 124 patients were treated according to routine care, comprising DAS < 2.4 steered
treatment. Percentages of DMARD-free remission (absence of synovitis for ≥ 1 year after DMARD cessation), late flares
(recurrence of clinical synovitis ≥ 1 year after DMARD cessation), and DMARD-free sustained remission (DMARD-free
remission sustained during complete follow-up) were compared between both treatment strategies.
Results: Patients receiving intensive treatment were younger and more often ACPA-positive. On a group level, there
was no significant association between intensive treatment and DMARD-free remission (35% vs 29%, corrected hazard
ratio (HR) 1.4, 95%CI 0.9–2.2), nor in ACPA-negative RA (49% versus 44%). In ACPA-positive RA intensive treatment
resulted in more DMARD-free remission (25% vs 6%, corrected HR 4.9, 95%CI 1.4–17). Intensive treatment was associated
with more late flares (20% versus 8%, HR 2.3, 95%CI 0.6–8.3). Subsequently, there was no difference in DMARD-free
sustained remission on a group level (28% versus 27%), nor in the ACPA-negative (43% versus 42%) or ACPA-positive
stratum (17% versus 6%, corrected HR 3.1, 95%CI 0.9–11).
Conclusions: Intensive treatment did not result in more DMARD-free sustained remission, compared to routine up-todate care. The data showed a tendency towards an effect of intensive treatment in ACPA-positive RA; this needs
further investigation